目前全球有4款獲批治療乳腺癌的細(xì)胞周期蛋白依賴性激酶（CDK）4/6抑制劑，分別是哌柏西利、瑞博西利、阿貝西利和達(dá)爾西利。其中，阿貝西利是繼哌柏西利和瑞博西利之后第3個(gè)進(jìn)入市場(chǎng)的CDK4/6抑制劑，可聯(lián)合芳香化酶抑制劑（AI）或他莫昔芬作為激素受體陽(yáng)性（HR⁺）、人表皮生長(zhǎng)因子受體2陰性（HER2^-）早期高危乳腺癌成人患者的輔助治療，還可聯(lián)合氟維司群或AI治療HR⁺/HER2^-局部晚期或轉(zhuǎn)移性乳腺癌。就阿貝西利治療激素受體陽(yáng)性乳腺癌的臨床研究進(jìn)展作以綜述，以期為臨床治療提供參考。

At present, there are four cyclin-dependent kinase 4/6 inhibitors approved for the treatment of breast cancer in the world, namely:Palbociclib, Ribociclib, Aabemaciclib and Dalpiciclib. Abemaciclib is the third CDK4/6 inhibitor to enter the market after Palbociclib and Ribociclib. It can be combined with aromatase inhibitors or tamoxifen as adjuvant therapy for adult patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR⁺/HER2^-) early high-risk breast cancer, and can also be combined with fulvestrant or AI in the treatment of HR⁺/HER2^- locally advanced or metastatic breast cancer. This article reviews the clinical research progress of abemaciclib in the treatment of hormone receptor positive breast cancer, in order to provide reference for clinical treatment.

R979.1

國(guó)家自然科學(xué)基金資助項(xiàng)目（82104553）